Inogen (NASDAQ:INGN) EVP Boyer Jennifer Yi Sells 10,938 Shares of Stock

Inogen, Inc (NASDAQ:INGN) EVP Boyer Jennifer Yi sold 10,938 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $6.60, for a total transaction of $72,190.80. Following the sale, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This trade represents a 68.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Inogen Trading Up 2.3%

Inogen stock opened at $6.75 on Tuesday. The stock has a market capitalization of $182.90 million, a price-to-earnings ratio of -7.41 and a beta of 1.58. The stock has a 50 day moving average of $6.60 and a two-hundred day moving average of $6.42. Inogen, Inc has a twelve month low of $5.34 and a twelve month high of $9.13.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.06). The company had revenue of $85.11 million for the quarter, compared to analyst estimates of $82.35 million. Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%. Equities analysts predict that Inogen, Inc will post -0.77 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on INGN shares. Freedom Capital raised Inogen to a “strong-buy” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research note on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Armistice Capital LLC raised its position in Inogen by 46.3% during the fourth quarter. Armistice Capital LLC now owns 1,264,000 shares of the medical technology company’s stock valued at $8,494,000 after acquiring an additional 400,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in shares of Inogen by 203.9% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 586,159 shares of the medical technology company’s stock valued at $3,622,000 after purchasing an additional 393,310 shares during the last quarter. CSM Advisors LLC bought a new stake in Inogen in the third quarter worth $2,973,000. Goldman Sachs Group Inc. raised its holdings in Inogen by 37.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 589,273 shares of the medical technology company’s stock valued at $3,960,000 after buying an additional 160,960 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Inogen by 30.1% in the first quarter. AQR Capital Management LLC now owns 564,032 shares of the medical technology company’s stock worth $4,022,000 after buying an additional 130,381 shares during the last quarter. Institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.